Loading...
•
Dec 31, 2022
Mesa Labs Q3 2023 Earnings Report
Mesa Labs' financial performance decreased slightly due to currency and COVID headwinds, but core organic revenue showed growth.
Key Takeaways
Mesa Labs reported a slight decrease in revenues for Q3 2023, but experienced growth in operating income and non-GAAP adjusted operating income. The company faced headwinds from currency exchange rates and COVID-19 impacts, but saw core organic revenue growth of 4.6%.
Revenues decreased by 1%, but non-GAAP core organic revenues grew by 4.6%.
Operating income increased significantly by 235%.
Non-GAAP adjusted operating income excluding unusual items decreased by 7%.
Clinical Genomics division was impacted by the closure of Sema4's expanded carrier screening business.
Mesa Labs
Mesa Labs
Mesa Labs Revenue by Segment
Revenue by Segment
Sterilization & Disinfection Control Revenue
CapyFin.comBiopharmaceutical Development Revenue
CapyFin.comCalibration Solutions Revenue
CapyFin.comClinical Genomics Revenue
CapyFin.com Forward Guidance
Mesa Labs enters the fourth quarter with clear short-term priorities for each division, expecting long-term growth opportunities in the regulated phases of the biopharmaceutical life cycle and the clinical genomics market.
Positive Outlook
- Clinical Genomics will be aided by the launch of a hereditary deafness Class 3 IVD panel in China by Guanzhou Darui.
- The panel received Chinese National Medical Products Administration (“NMPA”) approval in early January.
- This is the first Class 3 IVD panel based on our MassArray platform to receive such approval.
- Many more panels are in the pipeline.
- Raw materials availability improvements should enable sequential top line growth in 4Q23.
Challenges Ahead
- New systems orders for both the Clinical Genomics and Biopharmaceutical Development divisions were below expectations for the quarter.
- Improving consistent sale execution in those divisions remains a short-term priority for the company.
- Economic uncertainty in calendar year 2023 requires balancing margins and long-term growth investments.
- The primary gap to our long-term target is the approximate 3.5% headwind from Sema4.
- The quarter was strongly impacted by the previously announced closure of Sema4’s expanded carrier screening, an approximate $8,200 annual headwind that began fully impacting the business in 3Q23.
Revenue & Expenses
Visualization of income flow from segment revenue to net income